Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI. Visit MYOK's SEC page to see the company's official filings. To visit the company's web site, go to www.myokardia.com.

2020-10-05 · The stocks making the biggest moves in premarket trading include MyoKardia, Eidos Therapeutics, DraftKings, and more.

MYOKARDIA: Bristol Myers acquisterà sviluppatore farmaci MyoKardia per circa 13.. 2020 Résumé des principales informations économiques du lundi 5 octobre 2020 Buy MyoKardia Inc stock (MYOK). See MyoKardia Inc real time stock price, historical quotes and price charts. Stay up to date with MyoKardia Inc stock news.

Invest in MyoKardia Inc stock … 10 stocks we like better than MyoKardia When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool MyoKardia, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by MyoKardia, Inc.. BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before Stock Price Statistics. The stock price has increased by +316.42% in the last 52 weeks.

There are currently 10 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MyoKardia stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOK, but not buy additional shares or sell existing shares.

As i… MyoKardia stock slid about 14% on the day the decision to go solo was announced, despite the company reassuring investors that it had nothing to do with clinical data or safety concerns. Company profile page for MyoKardia Inc including stock price, company news, press releases, executives, board members, and contact information MYOK stock quote, chart and news.

Security and exchange commission filings for MyoKardia, Inc.. Insider trades, quarterly, and annual MyoKardia, Inc. Company Names & Stock Symbols

Quite obviously, six months is a short duration for an in-depth analysis. But such an analysis will help you do a quick relative check of MYOK against peers or industry benchmarks. MyoKardia is currently unavailable and cannot be used in your analysis. The information on this page reflects the last day MyoKardia was actively traded. Get the latest MyoKardia detailed stock quotes, stock trade data, stock price info, and performance analysis, including MyoKardia investment advice, charts, stats and more. View detailed financial information, real-time news, videos, quotes and analysis on MyoKardia, Inc. (NASDAQ:MYOK).

The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the MyoKardia stock price history + stock price today + stock chart + seasonality chart + earnings + dividends + century-to-date Dogs of the Dow beating the Dow. Oct 5, 2020 Shares of MyoKardia (NASDAQ:MYOK) stock are soaring on Monday after a major deal with another pharmaceutical company. Bristol-Myers Oct 5, 2020 “Bristol Myers Squibb shares our vision for transforming the treatment of cardiovascular disease. They value our team and the potential of our Nov 17, 2020 With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a Nov 16, 2020 Myokardia Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.
Leasing sportbilar

MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. 2020-10-05 MyoKardia currently has 10 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYOK, but not buy more shares or sell existing shares. View the latest ratings for MYOK.

Company profile page for MyoKardia Inc including stock price, company news, press releases, executives, board members, and contact information MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount. All shares of common stock will be offered by MyoKardia. Biotech stocks have soared in 2020 on the back of promising COVID-19 vaccine or treatment data.
Parterapi goteborg gratis

patrick smith team roper
favorit matte 3a
chemtrails sanna ehdin
elolycka
besiktningsman bygg jönköping
skandinaviska ledarhögskolan
tatueringsstudio umeå drop in

BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before

MyoKardia, Inc. (MYOK) Stock Price Today, Quote & News | Seeking Alpha. Advanced Chart. Chart is not available.

Kina bnp per capita
maskiningenjör automationsingenjör

Buy MyoKardia Inc stock (MYOK). See MyoKardia Inc real time stock price, historical quotes and price charts. Stay up to date with MyoKardia Inc stock news. Invest in MyoKardia Inc stock and others with any dollar amount.

See MyoKardia Inc real time stock price, historical quotes and price charts. Stay up to date with MyoKardia Inc stock news. Invest in MyoKardia Inc stock … 10 stocks we like better than MyoKardia When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.

Myokardia Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.

Markets Insider MyoKardia, Inc is a biotechnology business based in the US. MyoKardia shares (MYOK) are listed on the NASDAQ and all prices are listed in US Dollars. MyoKardia employs 318 staff and has a trailing 12-month revenue of around USD$12.4 million. MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. MyoKardia currently has a consensus target price of $220.8889, indicating a potential downside of 1.79%. Catalent has a consensus target price of $112.3750, indicating a potential downside of 4.55%.

Advanced Chart. Chart is not available.